Multiple bone scintigraphy metastatic lesions in correlation with breast carcinoma human epidermal growth factor receptor 2 neu and hormone receptor expression
Journal
European journal of nuclear medicine and molecular imaging
Date Issued
2020
Author(s)
Jankulovska A.
Lazareva, E.
Ilijovska, M.
DOI
10.1007/s00259-020-04988-4
Abstract
Aim/Introduction: Bone scintigraphy is a useful tool for the
accurate diagnosis of skeletal metastatic lesions among
oncological patients. Several factors have been proposed for
the prediction of osseous and/or visceral metastatic disease
onset in breast cancer patients. The aim of our study was to
determine the correlation between multiple bone metastatic
lesions initially diagnosed with bone scintigraphy and tumor
receptor characteristics of breast cancer patients. Materials
and Methods: We performed a monocentric (University Clinic
``Mother Theresa``), retrospective, observational study at the
Institute of Pathophysiology and Nuclear Medicine and the
Institute for Radiotherapy and Oncology in Skopje. Between
January 2013 and December 2018, 66 female breast cancer
patients (mean age 52,51 ± 10,64 years) who underwent initial
99mTc-MDP bone scintigraphy procedure and were diagnosed
with multiple skeletal metastatic lesions were included
in the study. Primary tumor characteristics regarding the
human epidermal growth factor receptor 2 neu - HER2neu
and hormone receptor - HR (estrogen receptor - ER and/or
progesterone receptor - PR) expression of each patient were
evaluated for association with multifocal osseous metastasis.
Results: Bone metastatic lesions were initially detected 5,59
± 2,72 years after the breast cancer diagnosis confirmation.
The axial skeleton was affected in 29% of patients and in 71%
the affection was both axial and appendicular. In our study
cohort, the spine (predominantly the thoracic segment),
the ribs and the pelvis were the most common sites of
metastatic involvement (p = 0.013). ER+ were 86% (57/66) of
the patients, PR+ were 74% (49/66) and HER2neu+ were 35%
(23/66). HR+/HER2neu- were 65% (43/66) of the patients,
HR+/HER2neu+ were 29% (19/66) and HR-/HE2neu+ were
6% (4/66). Multiple bone scintigraphy metastatic lesions
significantly correlated with HR+ status of breast cancer
patients (p = 0.021). Conclusion: Breast cancer patients
with hormone receptor-positive status present significant
predilection for skeletal metastatic patterns.
accurate diagnosis of skeletal metastatic lesions among
oncological patients. Several factors have been proposed for
the prediction of osseous and/or visceral metastatic disease
onset in breast cancer patients. The aim of our study was to
determine the correlation between multiple bone metastatic
lesions initially diagnosed with bone scintigraphy and tumor
receptor characteristics of breast cancer patients. Materials
and Methods: We performed a monocentric (University Clinic
``Mother Theresa``), retrospective, observational study at the
Institute of Pathophysiology and Nuclear Medicine and the
Institute for Radiotherapy and Oncology in Skopje. Between
January 2013 and December 2018, 66 female breast cancer
patients (mean age 52,51 ± 10,64 years) who underwent initial
99mTc-MDP bone scintigraphy procedure and were diagnosed
with multiple skeletal metastatic lesions were included
in the study. Primary tumor characteristics regarding the
human epidermal growth factor receptor 2 neu - HER2neu
and hormone receptor - HR (estrogen receptor - ER and/or
progesterone receptor - PR) expression of each patient were
evaluated for association with multifocal osseous metastasis.
Results: Bone metastatic lesions were initially detected 5,59
± 2,72 years after the breast cancer diagnosis confirmation.
The axial skeleton was affected in 29% of patients and in 71%
the affection was both axial and appendicular. In our study
cohort, the spine (predominantly the thoracic segment),
the ribs and the pelvis were the most common sites of
metastatic involvement (p = 0.013). ER+ were 86% (57/66) of
the patients, PR+ were 74% (49/66) and HER2neu+ were 35%
(23/66). HR+/HER2neu- were 65% (43/66) of the patients,
HR+/HER2neu+ were 29% (19/66) and HR-/HE2neu+ were
6% (4/66). Multiple bone scintigraphy metastatic lesions
significantly correlated with HR+ status of breast cancer
patients (p = 0.021). Conclusion: Breast cancer patients
with hormone receptor-positive status present significant
predilection for skeletal metastatic patterns.